G1 Therapeutics, Inc. short interest in 2023
In 2023, G1 Therapeutics, Inc.'s disclosed short interest ran from 7.19% of shares outstanding on 13 Jan 2023 to 5.36% on 29 Dec 2023, a change of -1.83 percentage points. The year's high was 9.81% on 31 Mar 2023 and its low 4.67% on 30 Nov 2023, averaging 6.20% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.43 days on 15 Sep 2023. Full history: G1 Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024
2023 in figures
- Start of year
- 7.19% (13 Jan 2023)
- End of year
- 5.36% (29 Dec 2023)
- Change
- -1.83 pp
- High
- 9.81% (31 Mar 2023)
- Low
- 4.67% (30 Nov 2023)
- Average
- 6.20%
- Highest days to cover
- 7.43 (15 Sep 2023)
- SEC filings marked
- 8
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 7.19% | 2.72 | |
| 31 Jan 2023 | 7.28% | 3.43 | |
| 15 Feb 2023 | 7.10% | 1.33 | |
| 28 Feb 2023 | 6.65% | 2.39 | |
| 15 Mar 2023 | 8.56% | 3.29 | 10-K filed, results (8-K) |
| 31 Mar 2023 | 9.81% | 3.90 | |
| 14 Apr 2023 | 8.80% | 6.12 | |
| 28 Apr 2023 | 6.42% | 5.17 | |
| 15 May 2023 | 6.03% | 2.64 | 10-Q filed, results (8-K) |
| 31 May 2023 | 5.72% | 3.59 | |
| 15 Jun 2023 | 4.98% | 3.48 | |
| 30 Jun 2023 | 5.98% | 4.25 | |
| 14 Jul 2023 | 6.04% | 5.58 | |
| 31 Jul 2023 | 6.30% | 3.02 | |
| 15 Aug 2023 | 5.67% | 1.54 | 10-Q filed, results (8-K) |
| 31 Aug 2023 | 5.66% | 6.19 | |
| 15 Sep 2023 | 5.59% | 7.43 | |
| 29 Sep 2023 | 5.36% | 5.81 | |
| 13 Oct 2023 | 5.03% | 5.21 | |
| 31 Oct 2023 | 4.70% | 3.22 | |
| 15 Nov 2023 | 4.80% | 4.67 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 4.67% | 4.60 | |
| 15 Dec 2023 | 5.09% | 1.00 | |
| 29 Dec 2023 | 5.36% | 2.74 |
See also: G1 Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.